GUEST COLUMNISTS

• Using Carbon Nanotubes To Pinpoint Optimal Harvest Time in Bioprocessing

  Cell-free expression systems confound the moment of peak expression. These nanosensors signal through crude lysate for process optimization and endpoint monitoring.

• U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact

  Beroe Inc.'s Mathini Ilancheran discusses the 2025 U.S. pharma tariff framework and translates it into actionable procurement and outsourcing responses.

• Tackling OSD Manufacturing Challenges With Pharma 4.0 Digital Innovation: Overview

  Pharma 4.0 smart manufacturing provides an effective way to tackle oral solid dosage challenges. Digital formulation modeling is one of four smart solutions discussed.

• Active Versus Passive Shipping Solutions For Clinical Shipments

  Explore active and passive temperature-controlled shipping solutions and their impact on clinical trial supply, balancing cost, risk, and product integrity.

• The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality

  The Trump administration has effectively merged national security, trade policy, and drug quality. Now, foreign manufacturers lacking deals face paying a "quality tax."

• January 2026 — CDMO Opportunities And Threats Report

  Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

• This Industrial Fungus Has Protein Expression Promise For Pharma

  Trichoderma reesei is well characterized for industrial uses. A Finnish research group is exploring it for pharmaceutical protein expression.

• Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy

  Cell and gene therapies share fundamental objectives with conventional biologics. Their common challenges offer a natural starting point to solving downstream bottlenecks.